BioWorld

Feb. 13, 2007

View Archived Issues

Onyx Skyrockets On Phase III Nexavar Data In Liver Cancer

Shares of Onyx Pharmaceuticals Inc. soared more than 95 percent on news that its kidney cancer drug, Nexavar, yielded positive survival data in a Phase III trial in liver cancer patients. (BioWorld Today) Read More

Panel Deliberates Ideas To Fund Global Health Products

Read More

CTI Spins Out Aequus To Develop Follow-On Biologics

Read More

Biodel Files For IPO To Fund Peptide Hormone Formulations

Read More

Other News To Note

Read More

Clinic Roundup

Read More